AYURVEDA IS NOT A MERE HERBAL MEDICINE / FOLKLORE
Does it offer new paths for Pharmaceutical Research?

By
Dr. Ashok D.B. Vaidya, M.D.Ph.D.
Medical & Research Director, Bhavan’s S.P.A.R.C., Mumbai 400 049.

Ayurveda is the mainstream health system for many Indians, for thousands of years. Currently, there are over 400,000 registered Ayurvedic practitioners. There are also formal educational, professional, R & D and governance institutions and structures in Ayurveda, which regulate and oversee the quality and health care performance. Notwithstanding this huge Indian base in Ayurveda, vested interests in the west are bent upon labeling Ayurveda as only another type of herbalism or folklore medicine. This has been criticized by Patel, Pandey, Gulati, Chopra, Vaidya, etc. Although alternative or complementary medicine is now gaining significant popularity in the west, Ayurveda is not at all given its due share, as a robust system of health care.

The prestigious medical journal – New England Journal of Medicine (NEJM), December 19, 2002 issue – had addressed the important debate related to herbal medicines by publishing three articles, but all these articles neither mentioned Ayurveda nor the important Ayurvedic plants of India. When an attempt was made to present facts through a letter to the Editor of NEJM, this was rejected without giving any reason. Another submission of a modified letter, requesting to reconsider their decision was also summarily rejected. This obviously bespeaks of the western European and American arrogance. The world is currently witnessing this arrogance on other fronts of life and death. This selective but dogged undermining of India and her contributions by the US and UK is unfair. It is to the disadvantage of the western populace that the healing wisdom of India suffers such a prejudice by the US and European medical and pharmaceutical establishments. On accessing the website of PUBMED of the US National Library of Medicine, with the keyword Ayurveda, one gets around 218 citations. But if one puts the query on Complementary or Alternative Medicine or Herbals, there are thousands of references. This prejudice against Ayurveda has to be handled by a careful strategy by the Indian Government, academia and industry. Then only Ayurveda will emerge as global medicine.
What criteria define a system of medicine/health? Table 1 lists the differences between Ayurveda and herbalism/folklore, based on some criteria.

**Table 1**

**Markers of a system vs a practice/folklore**

<table>
<thead>
<tr>
<th>Marker</th>
<th>Ayurveda</th>
<th>Herbalism</th>
</tr>
</thead>
<tbody>
<tr>
<td>Philosophical axioms</td>
<td>Shat – Darshanas(^{15})</td>
<td>Non existent</td>
</tr>
<tr>
<td>Nature of man</td>
<td>Katidha-purushiyam(^{16})</td>
<td>Tribal beliefs(^{17})</td>
</tr>
<tr>
<td>Roots and continuity</td>
<td>5000 years(^{18})</td>
<td>Discontinuities(^{19})</td>
</tr>
<tr>
<td>Authentic textbooks</td>
<td>Hundreds of books(^{20})</td>
<td>Mere compilations(^{21,22})</td>
</tr>
<tr>
<td>Academic institutes</td>
<td>Hundreds of centers(^{23})</td>
<td>Sporadic training(^{24})</td>
</tr>
<tr>
<td>Theories of pathogenesis</td>
<td>Tridosha-Saptadhatu(^{25})</td>
<td>Vague/demons/ancestors(^{26})</td>
</tr>
<tr>
<td>Prognostics</td>
<td>Sadhya-Asadhyata(^{27})</td>
<td>Uncertain indication(^{28})</td>
</tr>
<tr>
<td>Therapeutics</td>
<td>Rationale explained(^{29})</td>
<td>Empirical /faith(^{30})</td>
</tr>
<tr>
<td>Research &amp; Progress</td>
<td>Significant research(^{31})</td>
<td>Sporadic /anecdotal(^{32})</td>
</tr>
</tbody>
</table>

The Indian and multinational pharmaceutical industry has often tried to grab “Herbal Remedies” from Ayurveda, without first grasping the fundamentals of the system. Despite these lacunae there have been some remarkable successes of Ayurvedic remedies, often labeled as herbas or dietary supplements\(^{33}\), in the west. Table 2 lists only some of these well-acclaimed or relatively unknown major discoveries that influenced the current global pharmacology and therapeutics, based more on the allopathic paradigms.

**Table 2**

**Ayurvedic plants and global pharmacology**

<table>
<thead>
<tr>
<th>No.</th>
<th>Plant</th>
<th>Indication</th>
<th>Spin-offs and impact</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Rauwolfia Serpentina</td>
<td>Hypertension</td>
<td>Catecholamine depletion and new drugs(^{34})</td>
</tr>
<tr>
<td>2</td>
<td>Commiphora wightii</td>
<td>Hyperlipidemia(^{35})</td>
<td>Hepatic receptors &amp; lipid changes(^{36})</td>
</tr>
<tr>
<td>3</td>
<td>Glycyrrhiza glabra</td>
<td>Viral infections</td>
<td>Viral DNA synthesis and transcription(^{37})</td>
</tr>
<tr>
<td>4</td>
<td>Plantago ovata</td>
<td>Constipation</td>
<td>Bowel regulators &amp; lipid disorders</td>
</tr>
</tbody>
</table>
We need not forget that the Ayurvedic dravya-gunas of these and other Indian plants offer a much wider scope for Indian pharmaceutical R & D. The paradigm of the current research has to change to Reverse Pharmacology – a path proposed and utilized by the pioneers in Ayurveda. Figure 1 shows the stages and approaches in Reverse Pharmacology. We must emphasize Ayurvedic Pharmacoepidemiology and robust clinical documentation of Ayurvedic therapy – non-drug as well as with drugs. Such an approach, if committed to by the top management of the drug industry, can within five years make India a world leader in drug industry.

We can cost-effectively corporatize Ayurveda as a mainstream system of medicine, with a global impact. We need to synergise Ayurveda and Life Sciences, for products and services based on evidence.

Once the Indian Pharmaceutical industry takes up Ayurveda seriously, the new paths for products, prognotics, services and reparatives will certainly open up. But currently the Indian pharma industry leaders are only interested in R & D of the ME-TOO molecules. With the current resources at their disposal, this path is indeed fraught with hazards. One such example is recent debate of Reddy’s antidiabetic compound which after an apparent success showed urinary bladder carcinogenesis in mice and rats. The hype of Indian basic pharmaceutical R & D got a setback that was almost expected. The new paths which can be adopted are shown in Table 3.

### Table 3
**New paths for pharmaceutical research**

<table>
<thead>
<tr>
<th>Fields</th>
<th>Ayurveda – leads</th>
<th>New paths</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aging and disorders</td>
<td>Kayakalpa &amp;</td>
<td>Caloric deprivation &amp;</td>
</tr>
</tbody>
</table>
The leads from Ayurveda either from Shodhana (purificatory) or Shaman (alleviating) therapy need to be pursued further by in depth medical research. The molecular mechanisms of Ayurvedic drug actions do offer a major challenge in Reverse Pharmacology. The clinical effects of the entire plant or parts of it when understood, at the molecular or integrative levels, would provide truly novel paths for chemical drug development. These paths may involve combinatorial chemistry eg. 400 analogues of curcumin have been synthesized and are being screened. The high throughput screen or pharmacogenomics approach can be gainfully utilized. For this the targets are to be defined based on the clinical effects of the lead plant. Such a Reverse Genomics may yield totally new and rational targets for synthetic drug development.

Ayurvedic and modern drug manufacturers, academic and pharma R & D laboratories and government research councils should evolve well-defined new drug development plans for selected and prioritized diseases. The Council of Scientific and Industrial Research (CSIR), under its New Millennium Initiative for Technological Leadership of India (NMITLI), has already evolved certain major projects based on Reverse Pharmacology and network R & D. It is desirable that the Indian drug industry takes major initiatives for a research focus on Ayurveda and not merely pursue the new chemical entities or me-too's. It is likely that the research on phytopharmacological actions correlates with the clinical effects of Ayurvedic therapy. Then Ayurveda would be truly understood as a system and not as a folklore.
REFERENCES


23. www.indiamedicine.nic.in


41. So Young, Darric S.H.L. Kim. Discovery of Natural Products from Curcuma longa that protect cells from Beta – Amyloid Insult: A Drug Discovery Effort against Alzheimer’s Disease. J. of Natural Products 2002; 65(9): 1227-1231.

42. Singh N. et al. Melia azadirachta in some common skin disorders Antiseptic 1979; 76: 677.


47. Ethical Committee – Independent, Notes 2003 (personal communication).


50. Dahanukar S, Vaman in bronchial asthma (Abstract, Update Ayurveda, 2000, Mumbai.

51. Antarkar DS, Perspective on Ayurveda with special reference to mental health in Ayurvedic and Allopathic Medicine & Mental Health, Eds. V. Ravindranath, L.Brady, A.B.Vaidya et al. Bhavan’s SPARC.


FIGURE 1
THE FLOW CHART OF REVERSE PHARMACOLOGY

Besides Clin. Pharmac.  ➔  Robust Lead Documentation

Limited Phase I  ➔  Standardized Formulation

Dose – Range Evolved  ➔  Exploratory Open Phase 2

Controlled Clinical Trials  ➔  Experimental & Cellular Biochemical Pharmacology

Essential Toxicity Studies  ➔  Understanding Mechanisms

Large Scale MC Trials  ➔  Basic Drug Dossier Preparation

Indian and Global Use/Market